MX2022016148A - Formulaciones. - Google Patents

Formulaciones.

Info

Publication number
MX2022016148A
MX2022016148A MX2022016148A MX2022016148A MX2022016148A MX 2022016148 A MX2022016148 A MX 2022016148A MX 2022016148 A MX2022016148 A MX 2022016148A MX 2022016148 A MX2022016148 A MX 2022016148A MX 2022016148 A MX2022016148 A MX 2022016148A
Authority
MX
Mexico
Prior art keywords
formulations
treatment
pharmaceutically acceptable
acceptable salt
hiv infection
Prior art date
Application number
MX2022016148A
Other languages
English (en)
Inventor
Ian Paul Conn
Mark Robert Davies
Joanne Heafield
Jose Maria Fueyo
Trevor Martin Shreeves
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of MX2022016148A publication Critical patent/MX2022016148A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formulaciones que comprenden dolutegravir o una sal farmacéuticamente aceptable del mismo, abacavir o una sal farmacéuticamente aceptable del mismo y lamivudina, procesos para hacer tales formulaciones, y el uso de tales formulaciones en el tratamiento de la infección por VIH, en particular en el tratamiento de la infección por VIH en pacientes pediátricos.
MX2022016148A 2020-06-25 2021-06-23 Formulaciones. MX2022016148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2009685.5A GB202009685D0 (en) 2020-06-25 2020-06-25 Formulations
PCT/IB2021/055535 WO2021260569A1 (en) 2020-06-25 2021-06-23 Formulations

Publications (1)

Publication Number Publication Date
MX2022016148A true MX2022016148A (es) 2023-05-16

Family

ID=71949614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016148A MX2022016148A (es) 2020-06-25 2021-06-23 Formulaciones.

Country Status (15)

Country Link
US (1) US20230233470A1 (es)
EP (1) EP4171517A1 (es)
JP (1) JP2023531087A (es)
KR (1) KR20230027049A (es)
CN (1) CN115803018A (es)
AR (1) AR122720A1 (es)
AU (1) AU2021298249B2 (es)
BR (1) BR112022026126A2 (es)
CA (1) CA3180526A1 (es)
CL (1) CL2022003712A1 (es)
GB (1) GB202009685D0 (es)
IL (1) IL298351A (es)
MX (1) MX2022016148A (es)
TW (1) TW202216123A (es)
WO (1) WO2021260569A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119679802A (zh) * 2024-11-28 2025-03-25 安徽贝克生物制药有限公司 一种双层片剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2885763C (en) * 2012-10-23 2021-04-06 Cipla Limited Pharmaceutical antiretroviral composition
US20140234415A1 (en) * 2013-02-20 2014-08-21 Abbvie Inc. Tablet Dosage Forms
WO2015059466A1 (en) * 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
IN2014MU00916A (es) * 2014-03-20 2015-09-25 Cipla Ltd
EP3334419A1 (en) * 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz

Also Published As

Publication number Publication date
JP2023531087A (ja) 2023-07-20
CL2022003712A1 (es) 2023-06-30
EP4171517A1 (en) 2023-05-03
WO2021260569A1 (en) 2021-12-30
US20230233470A1 (en) 2023-07-27
BR112022026126A2 (pt) 2023-03-14
TW202216123A (zh) 2022-05-01
AR122720A1 (es) 2022-09-28
AU2021298249A1 (en) 2023-01-05
CA3180526A1 (en) 2021-12-30
AU2021298249B2 (en) 2024-07-11
KR20230027049A (ko) 2023-02-27
GB202009685D0 (en) 2020-08-12
CN115803018A (zh) 2023-03-14
IL298351A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
ZA202500439B (en) Therapeutic compounds for hiv virus infection
MX2021002321A (es) Nuevos metodos.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
JP2017057230A5 (es)
MY206814A (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
IL319866A (en) Ligand-drug conjugates of exatacan analogs and their medical use
MX2023001443A (es) Tratamiento con oligonucleotidos de pacientes con hepatitis b.
NZ799504A (en) Use of penehyclidine in treatment or prevention of vision-impairing eye diseases
EP4094774A4 (en) USE OF INTERFERON IN THE MANUFACTURE OF A MEDICATION FOR THE PREVENTION OF CORONAVIRUS INFECTION OR FOR THE PREVENTION OF DISEASES CAUSED BY CORONAVIRUS INFECTION
MX2022016148A (es) Formulaciones.
WO2022099187A3 (en) Sars-cov-2 antigen-binding proteins and uses thereof
EP4135698A4 (en) SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS
PA8517701A1 (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
ZA202300493B (en) Antiviral use of liraglutide and gefitinib
ZA202309001B (en) Abhd6 antagonist
WO2022026622A3 (en) Treatment of viral diseases
WO2022125378A8 (en) Combination therapy
WO2021205026A3 (en) Pharmaceutical composition for treatment of enveloped dna or rna virus induced infections and disorders
MX2022013722A (es) Cisteamina para el tratamiento de infección por sars-cov-2.
CL2022003743A1 (es) Formulaciones de tableta dispersable que comprenden dolutegravir
MX2022012693A (es) Composicion que comprende metilfolato.
DE60025826D1 (de) Pyrazolidinol-verbindungen
GEP20227432B (en) Therapy of high-risk human papillomavirus infections